Objective. To assess the efficacy and safety of Cellex for the correction of cognitive disorders in the acute period of ischemic stroke (IS). Materials and methods. The study included 246 patients in the acute period of IS. Patients were divided by random selection into two groups given Cellex or placebo for 10 days on the background of standard basal treatment. Patients were assessed dynamically in terms of neuropsychological status. Results and conclusions. This study showed that in patients with IS, mild and moderate cognitive impairments underwent faster and more marked regression when Cellex was prescribed (p < 0.05).